Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGFR | P43088 | 16/20 | 0.65 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.65 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20664829 | 0.80 | PTGFR (0.77) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL12962489 | 0.80 | PTGFR (0.77) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL3050352 | 0.79 | PTGFR (0.75) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL3056287 | 0.79 | PTGFR (0.79) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL29392750 | 0.79 | PTGFR (0.79) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL23352804 | 0.79 | PTGFR (0.75) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL3056284 | 0.79 | PTGFR (0.79) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL3056281 | 0.79 | PTGFR (0.79) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL11263715 | 0.79 | PTGFR (0.75) | PTGFRPTGER3ABCC4ABCB11TBXA2R | |
| SCHEMBL3050355 | 0.79 | PTGFR (0.75) | PTGFRPTGER3ABCC4ABCB11TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1963 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | ALCON INC (CH) | 2026-02-05 | — | — | US | claimed |
| EP-4608405-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Veradermics, Incorporated (US) | 2025-09-03 | — | — | EP | claimed |
| WO-2024091572-A1 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | VERADERMICS INCORPORATED (US) | 2024-05-02 | — | — | WO | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| US-20220401487-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2022-12-22 | — | — | US | claimed |
| US-11413309-B2 | Compositions and methods for immune cell modulation in adoptive immunotherapies | FATE THERAPEUTICS, INC. (US) | 2022-08-16 | — | — | US | claimed |
| US-20220088000-A1 | COMBINATION THERAPY | ALCON INC. (CH) | 2022-03-24 | — | — | US | claimed |
| EP-3934646-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | Aerie Pharmaceuticals, Inc. (US) | 2022-01-12 | — | — | EP | claimed |
| CN-113784727-A | Pharmaceutical compositions for treating ocular diseases or disorders | 爱瑞制药公司 | 2021-12-10 | — | — | CN | claimed |
| EP-3461484-B9 | DIMESYLATE SALTS OF 4-(3-AMINO-1-(ISOQUINOLIN-6-YLAMINO)-1-OXOPROPAN-2-YL)BENZYL, THEIR COMBINATIONS WITH PROSTAGLANDINS AND THE USE THEREOF IN THE TREATMENT OF OCULAR DISORDERS | AERIE PHARMACEUTICALS INC (US) | 2021-06-09 | — | — | EP | claimed |
| EP-0664707-B1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LAB INC (US) | 1997-06-04 | — | — | EP | claimed |
| US-5605922-A | VISION DISORDERS; SIDE EFFECT REDUCTION | ALCON LABORATORIES, INC. (US) | 1997-02-25 | — | — | US | claimed |
| US-5565492-A | Prostaglandin combinations in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1996-10-15 | — | — | US | claimed |
| WO-1996013267-A2 | COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF FOR THE TREATMENT OF GLAUCOMA | ALLERGAN (US) | 1996-05-09 | — | — | WO | claimed |
| US-5480900-A | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0664707-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA. | ALCON LAB INC (US) | 1995-08-02 | — | — | EP | claimed |
| EP-0639563-A2 | Use of cloprostenol, fluprostenol and their analogues for the manufacture of a medicament for the treatment of glaucoma and ocular hypertension | ALCON LABORATORIES, INC. (US) | 1995-02-22 | — | — | EP | claimed |
| US-5369128-A | Administering a prostaglandin and a peripheral A2 adrenergic agonist | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1994-11-29 | — | — | US | claimed |
| EP-0603800-A1 | Prostaglandin combinations in glaucoma therapy | ALCON LABORATORIES, INC. (US) | 1994-06-29 | — | — | EP | claimed |
| WO-1994008585-A1 | COMBINATIONS OF PROSTAGLANDINS AND CLONIDINE DERIVATIVES FOR THE TREATMENT OF GLAUCOMA | ALCON LABORATORIES, INC. (US) | 1994-04-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088000-A1 | COMBINATION THERAPY | PTGS1, PTGS2, PTGIS | PTGFR 12/4885PTGER3 11/4885ABCC4 1408/4885 |
| US-20260034056-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING OCULAR DISEASES OR DISORDERS | KDR, FLT4, FLT1 | PTGFR 63/4885PTGER3 125/4885ABCC4 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.